We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$868M
AUM Growth
+$59.7M
Cap. Flow
+$69.5M
Cap. Flow %
8.01%
Top 10 Hldgs %
48.78%
Holding
127
New
31
Increased
30
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$14.1M
2
APGE icon
Apogee Therapeutics
APGE
+$11.9M
3
CLYM
Climb Bio
CLYM
+$11.1M
4
ACLX
Arcellx
ACLX
+$8.7M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$8.33M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$9.7M
2
ABSI icon
Absci
ABSI
+$5.82M
3
CYTK icon
Cytokinetics
CYTK
+$5.61M
4
KRYS icon
Krystal Biotech
KRYS
+$4.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 65.41%
2 Financials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
26
Immunovant
IMVT
$8.04B
$9.14M 1.05%
346,088
+61,088
+21% +$1.74M
ATXS
27
DELISTED
Astria Therapeutics
ATXS
$8.88M 1.02%
975,606
+130,000
+15% +$1.27M
MORF
28
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.54M 0.98%
250,573
+25,573
+11% +$758K
INSM icon
29
Insmed
INSM
$23B
$8.38M 0.97%
+125,000
New +$4.85M
NAMS icon
30
NewAmsterdam Pharma
NAMS
$3.63B
$8.13M 0.94%
423,155
+136,955
+48% +$2.75M
RZLT icon
31
Rezolute
RZLT
$488M
$7.96M 0.92%
1,850,000
+250,000
+16% +$859K
MRUS
32
DELISTED
Merus
MRUS
$7.4M 0.85%
+125,000
New +$6.05M
AXSM icon
33
Axsome Therapeutics
AXSM
$12.5B
$6.44M 0.74%
80,000
-59,758
-43% -$4.42M
GERN icon
34
Geron
GERN
$937M
$6.36M 0.73%
1,500,000
-1,000,000
-40% -$3.9M
SVRA icon
35
Savara
SVRA
$1.18B
$6.23M 0.72%
1,546,850
+396,850
+35% +$1.77M
ERAS icon
36
Erasca
ERAS
$6.72B
$5.9M 0.68%
+2,499,431
New +$5.39M
CATX icon
37
Perspective Therapeutics
CATX
$333M
$5.48M 0.63%
550,000
+40,000
+8% +$578K
MIRM icon
38
Mirum Pharmaceuticals
MIRM
$6.84B
$5.3M 0.61%
155,000
-5,000
-3% -$131K
CGEM icon
39
Cullinan Oncology
CGEM
$1.07B
$4.6M 0.53%
263,817
+5,229
+2% +$111K
PCVX icon
40
Vaxcyte
PCVX
$8.1B
$4.53M 0.52%
60,000
-20,000
-25% -$1.36M
ELEV
41
DELISTED
Elevation Oncology
ELEV
$3.97M 0.46%
1,468,825
+200,000
+16% +$753K
HLVX
42
DELISTED
HilleVax
HLVX
$3.84M 0.44%
+265,859
New +$3.65M
MLYS icon
43
Mineralys Therapeutics
MLYS
$2.37B
$3.84M 0.44%
327,959
– –
ROIV icon
44
Roivant Sciences
ROIV
$25.4B
$3.72M 0.43%
351,587
-148,413
-30% -$1.63M
DYN icon
45
Dyne Therapeutics
DYN
$3.86B
$3.53M 0.41%
+100,000
New +$2.91M
PCSC
46
DELISTED
Perceptive Capital Solutions
PCSC
$3.52M 0.41%
+350,000
New +$3.53M
IMTX icon
47
Immatics
IMTX
$1.28B
$3.49M 0.4%
300,000
-50,000
-14% -$563K
XBI icon
48
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$3.48M 0.4%
+37,550
New +$3.37M
CNTX icon
49
Context Therapeutics
CNTX
$55.8M
$3.25M 0.37%
1,619,140
+1,290,323
+392% +$2.22M
BDTX icon
50
Black Diamond Therapeutics
BDTX
$104M
$3.03M 0.35%
+650,000
New +$3.49M
1
2
3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Affinity Asset Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Affinity Asset Advisors held 127 positions worth $868M, up 7.4% from $808M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Affinity Asset Advisors deployed $69.5M of net new capital in Q2 2024, opening 31 new positions and adding to 30 existing holdings. Its largest new stake was Climb Bio: 1,670,661 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 71% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $4.42M trimmed.

  • Affinity Asset Advisors's largest Q2 2024 buy was Climb Bio: 1,670,661 shares worth $11.9M.
  • Affinity Asset Advisors added most to Alkermes in Q2 2024, an estimated $14.1M increase.
  • Affinity Asset Advisors's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $4.42M.
  • Affinity Asset Advisors fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $9.7M.
  • Affinity Asset Advisors's ten largest holdings make up 49% of its $868M portfolio in Q2 2024.
  • Affinity Asset Advisors opened 31 new positions and closed 29 in Q2 2024.
  • Affinity Asset Advisors's portfolio value rose 7.4% quarter-over-quarter to $868M.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.